Key Metrics
CiteScore 

1.2
SJR 

Q4Oncology

SNIP 

0.67
Recommended pre-submission checks
Powered by 

Clinical Advances in Hematology and Oncology Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | MILLENNIUM MEDICAL PUBLISHING, INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2003 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers in Clinical Advances in Hematology and Oncology
Interpreting MRD results and integrating assays into practice.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O
Targeting BRAF V600E mutations in metastatic colorectal cancer.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O
MRD testing across the continuum of care.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O
Practical approach to MRD testing in breast cancer: Q&A.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O
Addressing late detection of systemic relapse, the clinical blind spot.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O
Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O
Interpreting MRD results and integrating assays into practice.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O
Targeting BRAF V600E mutations in metastatic colorectal cancer.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O
MRD testing across the continuum of care.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O
Practical approach to MRD testing in breast cancer: Q&A.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O
Addressing late detection of systemic relapse, the clinical blind spot.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O
Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer.
- 1 Jun 2026
- Clinical advances in hematology & oncology : H&O